SG11201407265RA - Novel ha binding agents - Google Patents
Novel ha binding agentsInfo
- Publication number
- SG11201407265RA SG11201407265RA SG11201407265RA SG11201407265RA SG11201407265RA SG 11201407265R A SG11201407265R A SG 11201407265RA SG 11201407265R A SG11201407265R A SG 11201407265RA SG 11201407265R A SG11201407265R A SG 11201407265RA SG 11201407265R A SG11201407265R A SG 11201407265RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cambridge
- novel
- suite
- pct
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 101710186708 Agglutinin Proteins 0.000 abstract 1
- 101710146024 Horcolin Proteins 0.000 abstract 1
- 101710189395 Lectin Proteins 0.000 abstract 1
- 101710179758 Mannose-specific lectin Proteins 0.000 abstract 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 abstract 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 November 2013 (14.11.2013) WIPOIPCT (10) International Publication Number WO 2013/170139 A1 (51) International Patent Classification: A61K39/42 (2006.01) A61P 31/16 (2006.01) C07K16/10 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 61/645,554 61/716,447 13/830,367 PCT/US2013/040534 10 May 2013 (10.05.2013) English English US US us 10 May 2012 (10.05.2012) 19 October 2012 (19.10.2012) 14 March 2013 (14.03.2013) (71) Applicant: VISTERRA, INC. [US/US]; One Kendall Square, Suite B3301, Building 300, 3rd Floor, Cambridge, MA 02139 (US). (72) Inventors: SHRIVER, Zachary; 16 Fairmont Avenue, Cambridge, MA 02139 (US). VISWANATHAN, Karthik; 3114 Stearns Hill Road, Waltham, MA 02451 (US). SUB- RAMANIAN, Vidya; 158 Summer Street, Apt 414, Somerville, MA 02143 (US). RAGURAM, Sasisekharan; 2 Barsky Ct, Princeton, NJ 08540 (US). (74) Agent: LU, Shihua; Lando & Anastasi LLP, Riverfront Office Park, One Main Street; Suite 1100, Cambridge, MA 02142 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: NOVEL HA BINDING AGENTS Heavy Chain FIG. 1 EVQLLESGGGLVKPGQSLKLSCAASGFTFTSYGMHWVRQPPGKGLEWVAVISYDGSYKYYADSVQG RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSRLRSLLYFEWLSQGYFNPWGAGTTLTVSSASr KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPSPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSW TVPSSSLGTQTYICNVNHKPSNTKVDKKVSPPKSCDKTHTCPPCPGTELLGGPSVFLFPPKPKDTL MISRTPEVTCin?VDVSHEDPEVKFNWYVDG¥BVHNAKTKPREEQXNSTYRWSVLTVLHQDWLNGK EYKCKVSHKALPAPX&XTX8KAKG8PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES NGQPENMyKTrpPVLDSDGSFFLYSKLTVDKSBMQQGNVFSCSVMHEALBNHYTQKSLSLSPGK (SEO ID NO: 94) ^ Light Chain o\ EfviVH {XS^^SLAVSL(:s!tRAl iA^ VKNYLAW7OGJ-QAPKLU : : V : WAS s VPDR^S^S^S^a i 5 arTmSIMAEINAVWCQOWmPPTPGGISmDttiGSVAAPSVFlFPPSIXaitCSGTASVVaiNNfYPftSAK ® VQWKVDPiAlQSSNSQESVTliGOSKQSTYSlSSTlTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGSC (SEQ ID NO: 9 5) rn i-H (57) Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigenbinding fragments thereof, that bind hem- © agglutinin protein of influenza viruses, and methods of their use.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261645554P | 2012-05-10 | 2012-05-10 | |
US201261716447P | 2012-10-19 | 2012-10-19 | |
US13/830,367 US9969794B2 (en) | 2012-05-10 | 2013-03-14 | HA binding agents |
PCT/US2013/040534 WO2013170139A1 (en) | 2012-05-10 | 2013-05-10 | Novel ha binding agents |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407265RA true SG11201407265RA (en) | 2014-12-30 |
Family
ID=49548781
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201605669WA SG10201605669WA (en) | 2012-05-10 | 2013-05-10 | Novel ha binding agents |
SG11201407265RA SG11201407265RA (en) | 2012-05-10 | 2013-05-10 | Novel ha binding agents |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201605669WA SG10201605669WA (en) | 2012-05-10 | 2013-05-10 | Novel ha binding agents |
Country Status (14)
Country | Link |
---|---|
US (4) | US9969794B2 (en) |
EP (2) | EP3689377A1 (en) |
JP (2) | JP6363066B2 (en) |
KR (2) | KR102194936B1 (en) |
CN (2) | CN104602709B (en) |
AU (3) | AU2013259371B2 (en) |
CA (1) | CA2872308C (en) |
CL (1) | CL2014003051A1 (en) |
ES (1) | ES2785306T3 (en) |
HK (1) | HK1208619A1 (en) |
IL (1) | IL235585B (en) |
MX (2) | MX366180B (en) |
SG (2) | SG10201605669WA (en) |
WO (1) | WO2013170139A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
WO2014152946A2 (en) | 2013-03-14 | 2014-09-25 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
AU2014236508A1 (en) | 2013-03-14 | 2015-09-17 | Contrafect Corporation | Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy |
TWI702229B (en) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | Human antibodies to influenza hemagglutinin |
CA2975655C (en) | 2015-02-05 | 2023-09-19 | Janssen Vaccines & Prevention B.V. | Binding molecules directed against influenza hemagglutinin and uses thereof |
AU2016246065B2 (en) * | 2015-04-08 | 2021-06-03 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
AU2016261299B2 (en) * | 2015-05-11 | 2019-12-05 | Janssen Vaccines & Prevention B.V. | Influenza virus neutralizing peptidomimetic compounds |
JP6423550B2 (en) * | 2015-06-03 | 2018-11-14 | シャアメン ユニバーシティ | Broad spectrum monoclonal anti-FluB antibodies and uses thereof |
WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
WO2017124050A1 (en) * | 2016-01-14 | 2017-07-20 | Bps Bioscience, Inc. | Anti-pd-1 antibodies and uses thereof |
EP3419663A1 (en) * | 2016-02-24 | 2019-01-02 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
JP6800591B2 (en) * | 2016-03-11 | 2020-12-16 | 国立大学法人 岡山大学 | Influenza remedy |
WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
US11780907B2 (en) | 2018-01-26 | 2023-10-10 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
GB201814959D0 (en) * | 2018-09-14 | 2018-10-31 | Secr Defence | Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses |
AU2020248404A1 (en) | 2019-03-25 | 2021-09-30 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
MX2022007207A (en) * | 2019-12-11 | 2022-07-12 | Visterra Inc | Compositions and methods for treating and preventing influenza. |
WO2023102398A2 (en) * | 2021-11-30 | 2023-06-08 | Sab, Llc | Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof |
Family Cites Families (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL23522C (en) | 1927-03-23 | |||
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IL63224A (en) | 1980-07-17 | 1985-05-31 | Scripps Clinic Res | Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4625015A (en) | 1982-08-23 | 1986-11-25 | Scripps Clinic & Research Foundation | Broad spectrum influenza antisera |
ZA836080B (en) | 1982-08-23 | 1984-04-25 | Scripps Clinic Res | Broad spectrum influenza antisera |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
JP2518607B2 (en) | 1985-08-29 | 1996-07-24 | 雪印乳業株式会社 | Monoclonal antibody against influenza A virus HA antigen and method for producing the same |
WO1988006882A1 (en) | 1987-03-13 | 1988-09-22 | Micro Vesicular Systems, Inc. | Lipid vesicles formed of surfactants and steroids |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
WO1989011298A1 (en) | 1988-05-27 | 1989-11-30 | Centocor, Inc. | Formulation for antibody reagents |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5589174A (en) | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
US6337070B1 (en) | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
GB9320597D0 (en) | 1993-10-06 | 1993-11-24 | Proteus Molecular Design | Improvements in and realting to vaccines |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
JP2996864B2 (en) | 1994-03-30 | 2000-01-11 | 寳酒造株式会社 | Antibody variable region DNA |
DE19643314A1 (en) | 1996-10-21 | 1998-04-23 | Boehringer Mannheim Gmbh | Monoclonal antibodies against the epitope YPYDVPDYA, process for their preparation and use |
FR2817869B1 (en) | 2000-12-07 | 2005-01-14 | Technopharm | MONOCLONAL HUMAN ANTIBODY DIRECTED AGAINST INFLUENZA VIRUS OR A FRAGMENT THEREOF |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
KR101130181B1 (en) | 2003-02-27 | 2012-03-28 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection |
WO2005018539A2 (en) | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
AU2004277466C1 (en) | 2003-10-01 | 2022-06-23 | Kyowa Kirin Co., Ltd. | Method of stabilizing antibody and stabilized solution-type antibody preparation |
PT2261376E (en) | 2003-11-04 | 2013-09-23 | Univ Tulane | Method of preventing virus:cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins |
AU2004290070A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
WO2005116270A2 (en) | 2004-05-18 | 2005-12-08 | Vical Incorporated | Influenza virus vaccine composition and method of use |
WO2005116260A2 (en) | 2004-05-25 | 2005-12-08 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
CA2591992A1 (en) * | 2004-12-22 | 2006-06-29 | The Salk Institute For Biological Studies | Compositions and methods for producing recombinant proteins |
US7572620B2 (en) | 2005-01-11 | 2009-08-11 | Wisconsin Alumni Research Foundation | H3 equine influenza A virus |
CA2598884A1 (en) | 2005-02-24 | 2006-10-05 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
CA2637837A1 (en) * | 2006-01-26 | 2007-08-09 | Hx Diagnostics, Inc. | Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof |
US8222204B2 (en) | 2006-05-03 | 2012-07-17 | The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC | Influenza inhibiting compositions and methods |
US20080014205A1 (en) | 2006-05-15 | 2008-01-17 | Lawrence Horowitz | Neutralizing Antibodies to Influenza Viruses |
BRPI0713671A2 (en) | 2006-06-16 | 2013-12-03 | Dow Agrosciences Llc | DNA SEQUENCES, VECTORS AND PROTEINS OF HEMAGLUTININ FROM AVIAN INFLUENZA |
WO2008028946A2 (en) | 2006-09-07 | 2008-03-13 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
US20100150941A1 (en) | 2006-09-13 | 2010-06-17 | Dso National Laboratories | Hemagglutinin antibody and uses thereof |
JP4625485B2 (en) | 2006-09-29 | 2011-02-02 | 財団法人大阪産業振興機構 | Monoclonal antibody against highly pathogenic avian influenza virus |
US8030029B2 (en) | 2007-01-23 | 2011-10-04 | Academia Sinica | Flu vaccines and methods of use thereof |
JP5346820B2 (en) | 2007-03-13 | 2013-11-20 | エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー | Antibodies against H5N1 subtype A influenza virus |
JP5779350B2 (en) | 2007-03-27 | 2015-09-16 | シー レーン バイオテクノロジーズ, エルエルシー | Constructs and libraries containing antibody surrogate light chain sequences |
EP2155787A4 (en) | 2007-05-11 | 2010-06-16 | Temasek Life Sciences Lab Ltd | H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance |
BRPI0811857A2 (en) | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | SIMPLE CHAIN FC (SCFC) REGIONS, AGLUTINATION POLYPEPTIDES UNDERSTANDING THEM AND RELATED METHODS. |
EP2716656B1 (en) | 2007-06-15 | 2016-10-12 | Xiamen University | Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof |
WO2008156763A2 (en) | 2007-06-15 | 2008-12-24 | The Board Of Trustees Of The Leland Stanford Junior University | Human neutralizing monoclonal antibodies to h5n1 influenza a virus |
AU2008297594B2 (en) | 2007-09-13 | 2013-06-20 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof |
WO2009035412A1 (en) | 2007-09-13 | 2009-03-19 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof |
FR2921928B1 (en) | 2007-10-08 | 2011-03-04 | Sanofi Pasteur | MONOCLONAL ANTIBODIES SPECIFIC TO INFLUENZA VIRUS HEMAGGLUTININ |
JP5705545B2 (en) | 2007-11-12 | 2015-04-22 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Novel vaccine against multiple subtypes of influenza virus |
WO2009073163A1 (en) | 2007-12-03 | 2009-06-11 | American Type Culture Collection (Atcc) | Avian influenza antibodies, compositions, and methods thereof |
US20110038935A1 (en) | 2007-12-06 | 2011-02-17 | Marasco Wayne A | Antibodies against influenza virus and methods of use thereof |
US7981428B2 (en) | 2008-01-23 | 2011-07-19 | Academia Sinica | Flu vaccines and methods of use thereof |
EP2250197B1 (en) | 2008-02-05 | 2016-05-11 | Temasek Life Sciences Laboratory Limited | Binding protein and epitope-blocking elisa for the universal detection of h5-subtype influenza viruses |
US8669046B2 (en) | 2008-03-12 | 2014-03-11 | Xuguang (Sean) Li | Reagents and methods for detecting influenza virus proteins |
ITTO20080204A1 (en) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | MONOCLONAL ANTIBODIES ACTIONS TO REACT WITH A PLURALITY OF SUBTIPS OF THE INFLUENTIAL VIRUS A |
US8658354B2 (en) | 2008-03-28 | 2014-02-25 | National University Corporation Hokkaido University | Anti-(influenza a virus subtype H5 hemagglutinin) monoclonal antibody |
AU2009228058A1 (en) | 2008-03-28 | 2009-10-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to viral antigens |
FI20080333A0 (en) | 2008-05-02 | 2008-05-02 | Glykos Finland Oy | Influenza virus nucleic acids and peptides |
ITTO20080398A1 (en) | 2008-05-27 | 2009-11-28 | Pomona Biotechnologies Llc | MONOCLONAL ANTIBODIES HAVING PROPERTY OF HOSUBLICTIC CROSS-NEUTRALIZATION FOR INFLUENTIAL VIRUSES OF SUBTIPLE TYPE H1 |
PT2285408T (en) | 2008-06-05 | 2019-02-01 | Ablynx Nv | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
SG192501A1 (en) | 2008-07-11 | 2013-08-30 | Medimmune Llc | Influenza hemagglutinin and neuraminidase variants |
JP2011528902A (en) * | 2008-07-25 | 2011-12-01 | インスティテュート・フォー・リサーチ・イン・バイオメディシン | Anti-influenza A virus neutralizing antibody and use thereof |
US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
US20120128684A1 (en) | 2008-08-25 | 2012-05-24 | Burnham Institute For Medical Research | Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use |
US20100061995A1 (en) | 2008-09-08 | 2010-03-11 | Damian Michael Carragher | Immunotherapy To Treat Or Prevent Viral Infection |
GB0818356D0 (en) | 2008-10-07 | 2008-11-12 | Istituto Superiore Di Sanito | Antibodies |
WO2010040281A1 (en) | 2008-10-09 | 2010-04-15 | 厦门大学 | Humanized antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof |
US9347043B2 (en) | 2008-10-22 | 2016-05-24 | Institute For Research In Biomedicine | Methods for producing antibodies from plasma cells |
US8540995B2 (en) | 2008-12-24 | 2013-09-24 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof |
US8975378B2 (en) | 2008-12-25 | 2015-03-10 | Osaka University | Human anti-human influenza virus antibody |
CA2760553A1 (en) | 2009-04-30 | 2010-11-04 | Jr. James E. Crowe | Monoclonal antibodies to influenza h1n1 virus and uses thereof |
US8470327B2 (en) | 2009-05-11 | 2013-06-25 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof |
CN102482345A (en) | 2009-05-13 | 2012-05-30 | 航道生物技术有限责任公司 | Neutralizing molecules to influenza viruses |
IT1395961B1 (en) | 2009-06-01 | 2012-11-02 | Pomona Biotechnologies Llc | MONOCLONAL ANTIBODIES AS A MEDICATION FOR THERAPEUTIC AND / OR PROFILACTIC TREATMENT OF INFLUENCIAL VIRUS INFECTIONS (H1N1) OF SWINE ORIGIN (S-OIV) |
WO2011003100A2 (en) | 2009-07-02 | 2011-01-06 | Massachusetts Institute Of Technology | Compositions and methods for diagnosing and/or treating influenza infection |
AU2010282415A1 (en) * | 2009-08-14 | 2012-03-08 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
WO2011041391A1 (en) | 2009-09-29 | 2011-04-07 | Fraunhofer Usa, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
EP2486054A4 (en) | 2009-10-09 | 2013-09-11 | Univ Emory | Recombinant antibodies against h1n1 influenza |
WO2011068143A1 (en) | 2009-12-03 | 2011-06-09 | 独立行政法人科学技術振興機構 | Antibody against influenza virus subtype h5 and use thereof |
JP2013060367A (en) | 2010-01-15 | 2013-04-04 | Osaka Univ | Anti-influenza antibody and device for detecting influenza |
ES2802623T3 (en) | 2010-01-27 | 2021-01-20 | Massachusetts Inst Technology | Polypeptide Agents Technically Designed for Broad Spectrum Targeted Neutralization of Influenza |
JPWO2011093217A1 (en) | 2010-01-29 | 2013-06-06 | 富士レビオ株式会社 | Anti-Panderic (H1N1) 2009 antibody and immunoassay method using the same |
JPWO2011096302A1 (en) | 2010-02-02 | 2013-06-10 | 国立大学法人名古屋大学 | Drug-resistant influenza virus specific antibody and use thereof |
JP2011160681A (en) | 2010-02-05 | 2011-08-25 | Japan Science & Technology Agency | Antibody against hemagglutinin of influenza a, and utilization thereof |
EA201400855A1 (en) | 2010-03-08 | 2014-11-28 | Селлтрион, Инк. | MONOCLONAL HUMAN ANTIBODIES OBTAINED FROM HUMAN B-CELLS AND HAVING NEUTRALIZING ACTIVITY AGAINST THE VIRUS AIRFLOWER |
EP2552485B1 (en) | 2010-03-26 | 2017-03-08 | Pomona Ricerca S.r.l. | Full-length immunoglobulins of the igg isotype capable of recognizing a heterosubtype neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament |
ES2687706T3 (en) | 2010-06-17 | 2018-10-26 | Trellis Bioscience, Llc | Useful antibodies in passive influenza immunization |
AU2011289275A1 (en) | 2010-08-12 | 2013-02-21 | Theraclone Sciences, Inc. | Anti-hemagglutinin antibody compositions and methods of use thereof |
US8992929B2 (en) | 2010-08-23 | 2015-03-31 | Temasek Life Sciences Laboratory Limited | Monoclonal antibody specific to major neutralizing epitope of influenza H5 hemagglutinin |
US9534042B2 (en) | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
EP2640405A4 (en) | 2010-09-21 | 2015-04-15 | Massachusetts Inst Technology | Human-adapted ha polypeptides, vaccines, and influenza treatment |
WO2012045001A2 (en) | 2010-09-30 | 2012-04-05 | Vanderbilt University | Influenza virus antibodies and immunogens and uses therefor |
US10226527B2 (en) | 2010-10-04 | 2019-03-12 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
WO2012054745A1 (en) | 2010-10-20 | 2012-04-26 | New York Blood Center, Inc. | Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection |
WO2012072788A1 (en) | 2010-12-02 | 2012-06-07 | Mab-Factory Gmbh | Vaccine against influenza h5n1 viruses, medicament and treatment of h5n1 viral infections |
US9469685B2 (en) | 2011-01-10 | 2016-10-18 | Emory University | Antibodies directed against influenza |
EA027054B1 (en) | 2011-07-14 | 2017-06-30 | Круселл Холланд Б.В. | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
SI2734545T1 (en) | 2011-07-18 | 2019-06-28 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
AU2012289926A1 (en) | 2011-08-03 | 2014-03-13 | Children's Medical Center Corporation | A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin |
GB201115214D0 (en) | 2011-09-02 | 2011-10-19 | Health Prot Agency | Influenza virus antibody compositions |
CN103030693B (en) | 2011-09-30 | 2015-03-11 | 中国科学院上海巴斯德研究所 | Neutralization molecule of high-pathogenicity avian influenza and preparation method thereof |
ES2641257T3 (en) | 2011-09-30 | 2017-11-08 | Celltrion, Inc. | Binding molecule that has neutralizing activity against influenza A virus produced from human B cells |
AU2012326025B2 (en) | 2011-10-18 | 2017-08-31 | Emory University | Antibodies directed against influenza |
KR20130059721A (en) | 2011-11-29 | 2013-06-07 | (주)셀트리온 | Human monoclonal antibody generated from human b-cells able to neutralize influenza a viruses |
JP6325451B2 (en) | 2011-12-02 | 2018-05-16 | アイム・セラピューティクス・べー・フェー | Antibodies specific for influenza A |
WO2013086052A2 (en) | 2011-12-05 | 2013-06-13 | Trellis Bioscience, Llc | Antibodies useful in passive influenza immunization |
KR101749316B1 (en) | 2011-12-15 | 2017-06-21 | (주) 에이프로젠 | A Highly Potent Broad-Spectrum Neutralizing Monoclonal Antibody Derived From H1N1-Infected Patients and Method Of Treatment of Virus By Using Thereof |
EP2814841A4 (en) | 2012-01-31 | 2015-06-17 | Univ Osaka | Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same |
MX360056B (en) | 2012-03-08 | 2018-10-19 | Janssen Vaccines & Prevention Bv | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof. |
EP3492101A3 (en) | 2012-05-10 | 2019-10-23 | Massachusetts Institute Of Technology | Agents for influenza neutralization |
US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
SG11201505744XA (en) | 2013-02-07 | 2015-08-28 | Massachusetts Inst Technology | Human adaptation of h5 influenza |
AU2014329609B2 (en) | 2013-10-02 | 2019-09-12 | Humabs Biomed Sa | Neutralizing anti-influenza A antibodies and uses thereof |
RU2682049C2 (en) | 2014-01-27 | 2019-03-14 | Дженентек, Инк. | H7n9 influenza a therapy |
WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
EP3419663A1 (en) | 2016-02-24 | 2019-01-02 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
-
2013
- 2013-03-14 US US13/830,367 patent/US9969794B2/en active Active
- 2013-05-10 SG SG10201605669WA patent/SG10201605669WA/en unknown
- 2013-05-10 JP JP2015511741A patent/JP6363066B2/en active Active
- 2013-05-10 KR KR1020147034141A patent/KR102194936B1/en active IP Right Grant
- 2013-05-10 SG SG11201407265RA patent/SG11201407265RA/en unknown
- 2013-05-10 WO PCT/US2013/040534 patent/WO2013170139A1/en active Application Filing
- 2013-05-10 CA CA2872308A patent/CA2872308C/en active Active
- 2013-05-10 CN CN201380031902.5A patent/CN104602709B/en active Active
- 2013-05-10 EP EP19217944.8A patent/EP3689377A1/en not_active Withdrawn
- 2013-05-10 CN CN201810727263.0A patent/CN108948189A/en active Pending
- 2013-05-10 EP EP13724695.5A patent/EP2846832B1/en active Active
- 2013-05-10 AU AU2013259371A patent/AU2013259371B2/en active Active
- 2013-05-10 ES ES13724695T patent/ES2785306T3/en active Active
- 2013-05-10 KR KR1020207036010A patent/KR102366115B1/en active IP Right Grant
- 2013-05-10 MX MX2014013668A patent/MX366180B/en active IP Right Grant
- 2013-10-10 US US14/051,405 patent/US8877200B2/en active Active
-
2014
- 2014-10-16 US US14/516,197 patent/US9096657B2/en active Active
- 2014-11-09 IL IL235585A patent/IL235585B/en active IP Right Grant
- 2014-11-10 CL CL2014003051A patent/CL2014003051A1/en unknown
- 2014-11-10 MX MX2019007921A patent/MX2019007921A/en unknown
-
2015
- 2015-09-17 HK HK15109132.3A patent/HK1208619A1/en unknown
-
2017
- 2017-11-01 JP JP2017211718A patent/JP6800828B2/en active Active
-
2018
- 2018-01-19 AU AU2018200451A patent/AU2018200451B2/en active Active
- 2018-04-02 US US15/943,220 patent/US10800835B2/en active Active
-
2019
- 2019-03-27 AU AU2019202107A patent/AU2019202107A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201407265RA (en) | Novel ha binding agents | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
SG11201908527SA (en) | High affinity mage-a1-specific tcrs and uses thereof | |
SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201811490XA (en) | Cd3 binding antibodies | |
SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
SG11201806419RA (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
SG11201407372UA (en) | Nampt inhibitors | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis |